COVID-19 Mortality in a Pediatric Patient with Hemoglobin SC Disease and Alpha-Thalassemia Trait

Joshua E Motelow1, Stacie Kahn1, Patrick T Wilson1

  • 1Department of Pediatrics, Division of Critical Care and Hospital Medicine, Columbia University Irving Medical Center, New York-Presbyterian Morgan Stanley Children's Hospital of New York, New York, NY, USA.

Insights

This case highlights a severe COVID-19 infection in a pediatric patient with HbSC disease and alpha-thalassemia trait. Vigilance is crucial when treating children with hemoglobinopathies during the pandemic.

Area of Science:

  • Pediatric Hematology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • The ongoing COVID-19 pandemic presents unique challenges in pediatric populations.
  • Patients with hemoglobinopathies may be at increased risk for severe outcomes from SARS-CoV-2 infection.

Observation:

  • A 12-year-old boy with HbSC disease and alpha-thalassemia trait presented with fever and respiratory distress.
  • He rapidly progressed to respiratory failure requiring mechanical ventilation and exchange transfusion.
  • Despite initial improvement, he experienced acute hypoxemia and cardiac arrest.

Findings:

  • The patient tested positive for SARS-CoV-2, with chest imaging concerning for acute chest syndrome.
  • Treatment included hydroxychloroquine, antibiotics, and enoxaparin for DVT prophylaxis.
  • This case illustrates a severe and unusual presentation of COVID-19 in a pediatric patient with a complex hemoglobinopathy.

Implications:

  • Healthcare providers must maintain high vigilance for severe COVID-19 presentations in pediatric patients with hemoglobinopathies.
  • Early recognition and aggressive management are critical for improving outcomes.
  • This case underscores the need for tailored treatment strategies in this vulnerable population.

Related Concept Videos

Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
36.4K
Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
6.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
75
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
51
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
59
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.4K